The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study.
Ivana Sestak
No relevant relationships to disclose
Yi Zhang
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Catherine A. Schnabel
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Brock Schroeder
Employment or Leadership Position - bioTheranostics
Stock Ownership - bioTheranostics
Mark Erlander
Consultant or Advisory Role - bioTheranostics
Stock Ownership - bioTheranostics
Honoraria - bioTheranostics
Paul E. Goss
No relevant relationships to disclose
Jack M. Cuzick
Consultant or Advisory Role - NanoString Technologies
Research Funding - bioTheranostics
Mitchell Dowsett
Consultant or Advisory Role - Genoptix; NanoString Technologies
Research Funding - AstraZeneca
Dennis Sgroi
No relevant relationships to disclose